Stephen B. Hanauer
Impact in
- Genetics top 0.01%
- Inflammatory Bowel Disease
- Epidemiology top 0.05%
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
Papers in
- Genetics 303
- Inflammatory Bowel Disease 303
- Epidemiology 160
- Microscopic Colitis 143
- Autoimmune and Inflammatory Disorders 24
- Co-authors
- William J. Sandborn (138 shared papers)Paul Rutgeerts (28 shared papers)Brian G. Feagan (61 shared papers)Jean‐Frédéric Colombel (37 shared papers)Douglas C. Wolf (19 shared papers)Gary R. Lichtenstein (24 shared papers)Allan Olson (15 shared papers)Stefan Schreiber (42 shared papers)
- Journals
- Gastroenterology (102 papers)The American Journal of Gastroenterology (58 papers)Inflammatory Bowel Diseases (50 papers)Journal of Crohn s and Colitis (37 papers)Clinical Gastroenterology and Hepatology (19 papers)
- Partner nations
- United StatesCanadaBelgium
In The Last Decade
Stephen B. Hanauer
393 papers receiving 24.4k citations
Stephen B. Hanauer's Hit Papers
Peers
Comparison fields: 5 of 147
- Genetics 17.5k
- Epidemiology 7.8k
- Gastroenterology 1.2k
- Immunology 3.7k
- Hematology 1.1k
Countries citing papers authored by Stephen B. Hanauer
This map shows the geographic impact of Stephen B. Hanauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen B. Hanauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen B. Hanauer more than expected).
Fields of papers citing papers by Stephen B. Hanauer
This network shows the impact of papers produced by Stephen B. Hanauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen B. Hanauer. The network helps show where Stephen B. Hanauer may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen B. Hanauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 416 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Hit paper breakdown → | 2002 | 3209 |
| 2 | Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2013 | 2090 |
| 3 | Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial Hit paper breakdown → | 2006 | 1284 |
| 4 | Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities Hit paper breakdown → | 2005 | 753 |
| 5 | Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab Hit paper breakdown → | 2007 | 743 |
| 6 | Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease Hit paper breakdown → | 2004 | 740 |
| 7 | Natalizumab Induction and Maintenance Therapy for Crohn's Disease Hit paper breakdown → | 2005 | 690 |
| 8 | Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Hit paper breakdown → | 2011 | 688 |
| 9 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed Hit paper breakdown → | 2014 | 541 |
| 10 | Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Hit paper breakdown → | 2004 | 501 |
| 11 | Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis Hit paper breakdown → | 2011 | 471 |
| 12 | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Hit paper breakdown → | 2011 | 445 |
| 13 | 2006 | 414 | |
| 14 | Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis Hit paper breakdown → | 2016 | 362 |
| 15 | Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2021 | 351 |
| 16 | 2013 | 332 | |
| 17 | Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions Hit paper breakdown → | 2015 | 325 |
| 18 | 1996 | 321 | |
| 19 | 2003 | 291 | |
| 20 | 2011 | 277 |
About Stephen B. Hanauer
Stephen B. Hanauer is a scholar working on Genetics, Epidemiology, Surgery, Immunology and Public Health, Environmental and Occupational Health, having authored 416 papers that have together received 25.0k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (303 papers), Microscopic Colitis (143 papers), Eosinophilic Esophagitis (54 papers), Immunodeficiency and Autoimmune Disorders (28 papers), Autoimmune and Inflammatory Disorders (24 papers), Helicobacter pylori-related gastroenterology studies (22 papers), Acute Lymphoblastic Leukemia research (21 papers) and Biosimilars and Bioanalytical Methods (18 papers). The work is most often cited by research in Genetics (17.5k citations), Epidemiology (7.8k citations), Gastroenterology (1.2k citations), Immunology (3.7k citations) and Hematology (1.1k citations). Stephen B. Hanauer has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Jean‐Frédéric Colombel, Douglas C. Wolf, Gary R. Lichtenstein, Allan Olson, Stefan Schreiber, Lloyd Mayer and Weihang Bao. Their work appears in journals such as Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases, Journal of Crohn s and Colitis and Clinical Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.